Loading...

Home
ETF
DTIL

DTIL

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

DTIL News

FDA Approval Enables Initiation of DMD Clinical Trial

5d agoNewsfilter

Precision BioSciences Receives FDA Approval for Clinical Trial

5d agoYahoo Finance

Precision BioSciences Advances PBGENE-HBV and PBGENE-DMD Trials, Data Updates Expected in 2026

Jan 12 2026Yahoo Finance

iECURE Secures FDA RMAT Designation for ECUR-506, Advancing OTC Deficiency Treatment

Jan 07 2026Newsfilter

Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet

Dec 01 2025NASDAQ.COM

Precision BioSciences Initiates $75 Million Stock and Warrant Sale

Nov 11 2025SeekingAlpha

Precision BioSciences Unveils $75 Million Common Stock, Pre-Funded Warrants, and Warrant Offering

Nov 10 2025Yahoo Finance

Precision BioSciences Unveils New Phase 1 PBGENE-HBV Findings at AASLD The Liver Meeting®, Highlighting Safety, Tolerability, and Dose-Dependent Antiviral Effects in Initial Three Cohorts

Nov 10 2025Newsfilter

Precision BioSciences Publishes Study in Nucleic Acids Research on High-Efficiency Gene Insertion Mechanisms in Dividing and Non-Dividing Cells with ARCUS Nucleases

Oct 09 2025Newsfilter

Precision BioSciences Unveils First U.S. Clinical Trial Site for ELIMINATE-B Study

Oct 07 2025Newsfilter

DFAS's Assets May Indicate a 15% Profit Opportunity

Oct 02 2025NASDAQ.COM

Precision BioSciences to Present Late-Breaking Poster at the 30th Annual World Muscle Society Congress

Sep 30 2025Newsfilter

Precision BioSciences Shares Phase 1 ELIMINATE-B Trial Data for PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Sep 12 2025Newsfilter

Precision BioSciences Reveals U.S. Patent for PBGENE-HBV Targeting Chronic Hepatitis B and Provides Program Status Update

Sep 08 2025Newsfilter

iECURE to Showcase Preliminary OTC-HOPE Clinical Trial Results for ECUR-506 in Ornithine Transcarbamylase Deficiency at the 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism

Aug 25 2025Newsfilter

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Aug 06 2025Newsfilter